学校法人順天堂　研究者情報データベース:::研究業績詳細:::

HOME　＞　研究業績詳細

研究業績詳細

野見山崇（ノミヤマタカシ）

研究テーマ	糖尿病の合併症と併存症
研究業績（論文）	1. Teragawa H, Morimoto T, Fujii Y, Ueda T, Sakuma M, Shimabukuro M, Arasaki O, Node K, Nomiyama T, Ueda S. Effect of anagliptin versus sitagliptin on renal function : subanalyzes from the REASON trial. Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy. 2022 March 3 ;15 :685-94. 2. Tanaka Y, Iwaya C, Kawanami T, Hamaguchi Y, Horikawa T, Shigeoka T, Yanase T, Kawanami D, Nomiyama T. Combined treatment with glucagon-like peptide-1 receptor agonist exendin-4 and metformin attenuates breast cancer growth. Diabetol Int. 2021 Nov 25;13(3):480-492 3. Yamamoto L, Yamashita S, Nomiyama T, Kawanami T, Hamagichi Y, Shigeoka T, Horikawa T, Tanaka Y, Yanase T, Kawanami D, Iwasaki A. Sodium-glucose cotransporter 2 inhibitor canagliflozin attenuates lung cancer cell proliferation in vitro. Diabetol Int 2021 Feb 16 ;12(4) :389-398 4. Teragawa H, Morimoto T, Fujii Y, Ueda T, Sakuma M, Shimabukuro M, Arasaki O, Node K, Nomiyama T, Ueda S. Effect of anagliptin versus sitagliptin on inflammatory markers : sub-analysis from REASON trial. Diabetes Metab Syndr Obes 2020 Dec 15 :13 ;4993-5001 5. Furuhashi M, Sakuma I, Morimoto T, Higashiura Y, Sakai A, Matsumoto M, Sakuma M, Shimabukuro M, Nomiyama T, Arasaki O, Node K, Ueda S. Differential effect of DPP-4 inhibitors, anagliptin and sitagliptin, on PCSK9 levels in patients with type 2 siabetes mellitus who are receiving statin therapy. J Atheroscler Thromb 2020 Dec 18. Doi : 10.5551 6. Horikawa T, Kawanami T, Hamaguchi Y, Tanaka Y, Kita S, Ryorin R, Takashi Y, Tanabe M, Yanase T, Kawanami D, Nomiyama T. Pemafibrate, a PPAR alpha agonist, attenuates neointima formation after vascular injury in mice fed normal chow and a high-fat diet. Heliyon 2020 Nov 6 ;6(11) :e05431. 7. Nomiyama T. Can SGLT2 inhiitor be used for diabetes mellitus or vascular diseases ? J Atheroscler Thromb 2020 Nov 1 ;27(11) :1139-1140. 8. Furuhashi M, Sakuma I, Morimoto T, Higashiura Y, Sakai A, Matsumoto M, Sakuma M, Shimabukuro M, Nomiyama T, Arasaki O, Node K, Ueda S. Independent and distinct association of FABP4 and FABP5 with metabolic parameters in type 2 diabetes mellitus. Front Endocrinol (Lausanne). 2020 Sep 23 ;11 :575557. 9. Furuhashi M, Sakuma I, Morimoto T, Higashiura Y, Sakai A, Matsumoto M, Sakuma M, Shimabukuro M, Nomiyama T, Arasaki O, Node K, Ueda S. Treatment with anagliptin, a DPP-4 inhibitor, decrease FABP4 concentration in patients with type 2 diabetes mellitus at a high risk for cardiovascular disease who a receiving statin therapy. Cardiovasc Diabetol 2020 June ;9(1) :154. 10. Shigeoka T, Nomiyama T, Kawanami T, Hamaguchi Y, Horikawa T, Tanaka T, Irie S, Motonaga R, Hamanoue N, Tanabe M, Nabeshima K, Tanaka M, Yanase T, Kawanami D. Activation of overexpressed GLP-1R attenuates prostate cancer growth by inhibiting cell cycle progression. J Diabetes Investig 2020 Mar 7; 11(3):1137-1149. 11. Terawaki Y, Iwaya C, Nomiyama T, Shimono D, Horikawa T, Fujimura-Tanaka Y, Shigeoka T, Hamanoue N, Motonaga R, Tanabe M, Yanase T, Kawanami D. Efficacy and safety of a combination of an insulin secretagogue and a dipeptidyl peptidase-4 inhibitor in Japanese patients with type 2 diabetes mellitus ; the repaglinide glucose oscillation study in Fukuoka (REGO-F). Daibetol Int 2020 Feb ;11(3) :274-282. 12. Hirai H, Higa M, Morimoto T, Sakuma M, Arasaki O, Nomiyama T, Ueda S, Shimabukuro M. Dissimilar effects of anagliptin and sitagliptin on lipoprotein subclass in standard or strong statin-treated patients with type-2 diabetes mellitus : a subanalysis of the REASON (Randomized Evaluation of Anagliptin versus Sitagliptin on Low-Density LipoproteiN Cholesterol in Diabetes) trial. J Clin Med 2019 Dec 30 ;9(1) :93. 13. Komatsu S, Nomiyama T, Numata T, Kawanami T, Hamaguchi Y, Iwaya C, Horikawa T, Tanaka YF, Hamanoue N, Motonaga R, Tanabe M, Inoue R, Yanase T, Kawanami D. SGLT2 inhibitor ipragliflozin attenuates breast cancer cell proliferation. Endocr J 2020 Jan 28;67(1):99-106. 14. Chihara A, Tanaka A, Morimoto T, Sakuma M, Shimabukuro M, Nomiyama T, Arasaki O, Ueda S, Node K. Differences in lipid metabolism between anagliptin and sitagliptin in patients with type 2 diabetes on statin therapy : a secondry analysis of the REASON trial. Cardiovasc Diabetol 2019 Nov 16;18(1):158 15. Morimoto T, Sakuma M, Tokushige A, Natsuaki M, Asahi T, Shimabukuro M, Nomiyama T, Arasaki O, Node K, Ueda S. Randomized evaluation of anagliptin vs sitagliptin on low-density lipoprotein cholesterol in diabetes (REASON) trial : a 52 week, open-label, radomized clinical trial. Sci Rep 2019 Jun 12 ;9(1) :8537 16. Fujihara Y, Hamanoue N, Yano H, Tanabe M, Akehi Y, Nomiyama T, Yanase T. High sex hormone-binding globulin concentration is a risk factor for high fibrosis-4 index in middle-aged Japanese men. Endocr J 2019 Jul 28;66(7):637-645. 17. Takahashi H, Nomiyama T, Terawaki Y, Horikawa T, Kawanami T, Hamaguchi Y, Tanaka T, Motonaga R, Fukuda T, Tanabe M, Yanase T. Combined treatment with DPP-4 inhibitor linagliptin and SGLT2 inhibitor empagliflozin attenuates neointima formation after vascular injury in diabetic mice. Biochem Biophys Rep 2019 Apr 19 ;18 :100640. 18. Ohe K, Tanaka T, Horita Y, Harada Y, Yamasaki T, Abe I, Tanabe M, Nomiyama T, Kobayashi K, Enjoji M, Yanase T. Circular IRE-type RNAs of the NR5A1 gene are formed in adrenocortical cells. Biochem Biophys Res Commun 2019 Apr 23;512(1):1-6 19. Muta Y, Tanaka T, Hamaguchi Y, Hamanoue N, Motonaga R, Tanabe M, Nomiyama T, Nawata H, Yanase T. Selective androgen receptor modulator, S42 has anabolic effects on cultured myotubes. Biochem Biophys Rep 2019 Jan 15 ;17 :177-181 20. Takahashi H, Nomiyama T, Terawaki Y, Kawanami T, Hamaguchi Y, Tanaka T, Tanabe M, Bruemmer D, Yanase T. Glucagon-like peptide-1 receptor agonist exendin-4 attenuates neuron- derived orphan receptor 1 expression in vascular smooth muscle cells. J Atheroscler Thromb 2019 Feb 1 ;26(2) : 183-197 21. Nomiyama T, Shimono D, Horikawa T, Fujimura Y, Ohsako T, Terawaki Y, Fukuda T, Motonaga R, Tanabe M, Yanase T. Efficacy and safety of sodium–glucose cotransporter 2 inhibitor ipragliflozin on glycemic control and cardiovascular parameters in Japanese patients with type 2 diabetes mellitus; Fukuoka Study of Ipragliflozin (FUSION). Endocr J 2018 Aug 27;65(8):859-867 22. Kawanami T, Tanaka T, Hamaguchi Y, Nomiyama T, Nawata H, Yanase T. Selective androgen receptor modulator S42 suppresses prostate cancer cell proliferation. Endocrinology 2018 Apr 1;159(4):1774-1792. 23. Ueda S, Shimabukuro M, Arasaki O, Node K, Nomiyama T, Morimoto T. Effect of anagliptin and sitagliptin on low-density lipoprotein cholesterol in type 2 diabetic patients with dyslipidemia and cardiovascular risk : rationale and study design of the REASON trial. Cardiovasc Drug Ther 2018 Feb ;32(1) :73-80. 24. Iwaya C, Nomiyama T, Komatsu S, Kawanami T, Hamaguchi Y, Yoshinaga Y, Yamashita S, Tanaka T, Terawaki Y, Tanabe M, Nabeshima K, Iwasaki A, Yanase T. Exendin-4, a glucagon-like peptide-1 receptor agonist, attenuates breast cancer growth by inhibiting NF-kB activation. Endocrinology 2017 Dec 1 ;158(12) :4218-4232. 25. Yanase T, Kawanami T, Tanaka T, Tanabe M, Nomiyama T. Impact of metabolic disorders on prostate cancer growth : Androgen and insulin resistance. Reprod Med Biol 2017 ;16 :252-257 26. Hamanoue N, Tanabe M, Tanaka T, Akehi Y, Murakami J, Nomiyama T, Yanase T. A high score on the aging males’ symptoms scale is associated with insulin resistance in middle-aged men. Endocr J 2017 May 30 ;64(5) :521-530 27. Akehi Y, Hashimoto Y, Meren J, Tanabe M, Nomiyam T, Yanase T. Postpartum hypothalamic adorenal insufficiency with remission : A rare case. Endoc J 2017 Feb 27 ;64(2) :157-162 28. Fukuda T, Tanaka T, Hamaguchi Y, Kawanami T, Nomiyama T, Yanase T. Augmented growth hormone secretion and Stat3 phosphorylation in an aryl hydrocarbon receptor interacting protein (AIP)-disrupted somatotroph cell line. PLOS ONE 2016 ;11(10) :e0164131 29. Nomiyama T, Yanase T. GLP-1 receptor agonist as treatment for cancer as well as diabetes : beyond glucose control. Expert Review of Endocrinology & Metabolism 2016 ; 11(4), 357-364 30. Tanabe M, Motonaga R, Terawaki Y, Nomiyama T, Yanase T. Prescription of oral hypoglycemic agents in patients with type-2 diabetes mellitus : a retrospective cohort study using Japanese hospital database. J Diabete Invest 2017 Mar ;8(2) :227-234 31. Tsutsumi Y, Nomiyama T, Kawanami T, Hamagichi Y, Terawaki Y, Tanaka T, Murase K, Motonaga R, Tanabe M, Yanase T. Combined treatment with Exendin-4 and metformin attenuates prostate cancer growth. PLOS ONE 2015 Oct 6 ;10(10) :e0139709 32. Tanabe M, Nomiyama T, Motonaga R, Murase K, Yanase T. Reduced vascular events in type 2 diabetes by biguanide relative to sulfonylurea : study in a Jananese Hopital Database. BMC Endocr Disord 2015 Sep 17 ; 15(1) :49 33. Aoyagi N, Umemoto G, Nomiyama T, Yoshimura C, Ota C, Miyazaki S, Murase K, Nagaishi R, Watanabe K, Yanase T, Kikuta T. Rapid improvement of blood glucose level after prosthetic mandibular advancement in apatient with diabetes mellitus and obstructive sleep apnea. Diabetes Res Open J 2015 ; 1(3) : 67-71 34. Aoyagi N, Umemoto G, Nomiyama T, Yoshimura C, Ota C, Miyazaki S, Murase K, Nagaishi R, Yanase T, Kikuta T. Short-term effect of prosthetic mandibular advancement on glycemic control in diabetic patients with obstructive sleep apnea syndrome. Med Bull Fukuoka Univ 2015 ; 41(1), 145-152 35. Terawaki Y, Nomiyama T, Takahashi H, Tsutsumi Y, Murase K, Nagaishi R, Tanabe M, Kudo T, Kobayashi K, Yasuno T, Nakashima H, Yanase T. Efficacy of dipeptidyl peptidase-4 inhibitor linagliptin in patients with type 2 diabetes undergoing hemodialysis. Diabetol Metab Syndr 2015 May 17;7:44. 36. Zhao Y, Nomiyama T, Findeisen HM, Qing H, Aono J, Heywood EB, Bruemmer D. Epigenetic regulation of the NR4A orphan nuclear receptor NOR1 by histone acetylation. FEBS Lett 2014 Dec 20 ;588(24) :4825-30. 37. Terawaki Y, Nomiyama T, Kawanami T, Hamaguchi Y, Takahashi H, Tanaka T, Murase K, Nagaishi R, Tanabe M, Yanase T. Dipeptidyl peptidase-4 inhibitor linagliptin attenuates neointima formation after vascular injury. Cardiovasc Diabetol 2014, 13 :154 38. Tanabe M, Akehi Y, Nomiyama T, Murakami J, Yanase T. Total testosterone is the most valuable indicator of metabolic syndrome among various testosterone values in middle-aged Japanese men. Endocrin J 2015;62(2):123-32. 39. Nomiyama T, Kawanami T, Irie S, Hamaguchi Y, Terawaki Y, Murase K, Tsutsumi Y, Nagaishi R, Tanabe M, Morinaga H, Tanaka T, Mizoguchi M, Nabeshima K, Tanaka M, Yanase T. Exendin-4, a glucagon-like peptide-1 receptor agonist, attenuates prostate cancer growth. Diabetes 2014 Nov;63(11):3891-905. 40. Murase K, Nagaishi R, Takenoshita H, Nomiyama T, Akehi Y, Yanase T, Prevalence and clinical characteristics of primary aldosteronism in Japanese patients with type 2 diabetes mellitus and hypertension. Endocr J 2013 Aug 31;60(8):967-76. 41. Akehi Y, Kawate H, Murase K, Nagaishi R, Nomiyama T, Nomura M, Takayanagi R, Yanase T, Proposed diagnostic criteria for subclinical Cushing’s syndrome associated with adorenal incidentaloma. Endocr J 2013 Jul 30 ;60(7) :903-12 42. Terawaki Y, Nomiyama T, Akehi Y, Takenoshita H, Nagaishi R, Tsutsumi Y, Murase K, Nagasako H, Hamanoue N, Sugimoto K, Takada A, Ito K, Abe Y, Sasatomi Y, Ogahara S, Nakashima H, Saito T, Yanase T, The efficacy of incretin therapy in patients with type 2 diabetes undergoing hemodialysis. Diabetology and Metab Synd 2013 Feb 28;5(1):10 43. Ervinna N, Mita T, Yasunari E, Azuma K, Tanaka R, Fujimura S, Sukmawati D, Nomiyama T, Kanazawa A, Kawamori R, Fujitani Y, Watada H. Anagliptin, a DPP-4 inhibitor, suppresses proliferation of vascular smooth muscles and monocyte inflammatory reaction and attenuates atherosclerosis in male apo E-deficient mice. Endocrinology 2013 Mar ;154(3) :1260-70 44. Noda K, Zhang B, Iwata A, Nishikawa H, Ogawa M, Nomiyama T, Miura S, Sakou H, Matsuo K, Yahiro E, Yanase T, Saku K Lifestyle changes through the use of delivered meals and dietary counseling in a single-blind study: the STYLIST study. Circ J 2012 June;76(6)1335-1344 45. Mita T, Azuma K, Goto H, Jin WL, Arakawa M, NomiyamaT, Suzuki R, Kubota N, Tobe K, Kadowaki T, Fujitani Y, Hirose T, Kawamori R, Watada H. IRS-2 deficiency in macrophages promotes their accumulation in the vascular wall. Biochem Biophys Res Commun 2011 Dec 2;415(4):545-50 46. Nomiyama T, Akehi Y, Takenoshita H, Nagaishi R, Terawaki Y, Nagasako H, Kudo T, Kodera T, Kobayashi K, Urata H, Yanase T, members of CHAT. Contributing factors related to efficacy of the dipeptidyl peptidase-4 inhibitor sitagliptin in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract. 2012 Feb ;95(2) :e27-8 47. Gizard F, Zhao Y, Findeisen HM, Qing H, Cohn D, Heywood EB, Jones KL, Nomiyama T, Bruemmer D. Transcriptional regulation of the S-Phase kinase-associated protein 2 by the NR4A orphan nuclear receptor NOR1 in vascular smooth muscle cells. J Biol Chem 2011 Oct 14 ;286(41) :38485-93 48. Goto H, Nomiyama T, Mita T, Yasunari E, Azuma K, Komiya K, Arakawa M, Jin WL, Kanazawa A, Kawamori R, Fujitani Y, Hirose T, Watada T. Exendin-4, a glucagon-like peptide-1 receptor agonist, reduces intimal thickening after vascular injury. Biochem Biophys Res Commun 2011 Feb 4;405(1):71-84 49. Zhao Y, Howatt DA, Gizard F, Nomiyama T, Findeisen HM, Heywood EB, Jones KL, Conneely OM, Daugherty A, Bruemmer. Deficiency of the NR4A orphan nuclear receptor NOR1 decreases monocyte adhesion and atherosclerosis. Circ Res. 2010 Aug 20;107(4):501-11. 50. Mita T, Goto H, Azuma K, Jin WL, Nomiyama T, Fujitani, Hirose T, Kawamori R, Watada H. Impact of insulin resistance on enhanced monocyte adhesion to endothelial cells and atherosclerosis independeny of LDL cholesterol level. Biochem Biophys Res Commun 2010 May 14;395(4):477-83. 51. Arakawa M, Mita T, Azuma K, Ebato C, Goto H, Nomiyama T, Fujitani Y, Hirose T, Kawamori R, Watada H. Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes 2010 Apr;59(4):1030-7. 52. Nomiyama T, Watada H, ARB as a drug for diabetic microangiopathy. Nihon. Rinsho 2009 Apr;67(4):777-82. (in Japanese) 53. Tamura Y, Watada H, Tanaka Y, Daimaru N, Nomiyama T, Sakuraba K, Sawaki K, Kawamori R. Preliminary report: mitochondrial DNA 5178 polymorphism in male elite Japanese endurance runners. Matabolism 2009 Jan;59(1):62-3. 54. Nomiyama T, Zhao Y, Gizard F, Findeisen HM, Heywood EB, Jones KL, Conneely OM, Bruemmer D. Deficiency of the NR4A Neuron-Derived Orphan Receptor-1 Attenuates Neointima Formation After Vascular Injury. Circulation 2009 Feb 3;119(4):577-86. 55. Gizard F, Nomiyama T, Zhao Y, Findeisen HM, Heywood EB, Jones KL, Stales B, Bruemmer D. The PPAR (alpha)/p16INK4a Pathway Inhibits Vascular Smooth Muscle Cell Proliferation by Repressing Cell Cycle-Dependent Telomerase Activation. Circ Res. 2008 Nov 7;103(10):1155-63. 56. Nomiyama T, Bruemmer D. Liver X receptor as therapeutic targets in metabolism and atherosclerosis. Curr Atheroscler Rep. 2008 Feb;10(1):88-95 57. Tamura Y, Watada H, Igarashi Y, Nomiyama T, Onishi T, Takahashi K, Doi S, Katamoto S, Hirose T, Tanaka Y, Kawamori R. Short-term effects of dietary fat on intramyocellular lipid in sprinters and endurance runners. Metabolism 2008 Mar; 57(3):373-9 58. Nomiyama T, Perez-Tilve D, Ogawa D, Gizard F, Zhao Y, Heywood EB, Jones KL, Kawamori R, Cassis LA, Tschop MH, Bruemmer D. Osteopontin mediates obesity-induced adipose tissue macrophage infiltration and insulin resistance in mice. J Clin Invest 2007 Oct 1;117(10):2877-2888 59. Nakamachi T, Nomiyama T, Gizard F, Heywood EB, Jones KL, Zao Y, Fuentes L, Takebayashi K, Aso Y, Staels B, Inukai T, Bruemmer D. PPARalpha agonists suppress osteopontin expression in macrophages and decrease plasma levels in patients with type 2 diabetes. Diabetes 2007 Jun;56(6): 1662-7 60. Tamura Y, Ogihara T, Uchida T, Ikeda F, Kumashiro N, Nomiyama T, Sato F, Hirose T, Tanaka Y, Mochizuki H, Kawamori R, Watada H. Amelioration of glucose tolerance by hepatic inhibition of nuclear factor kappaB in db/db mice. Diabetologia. 2007 Jan;50(1):131-41 61. M. Kapoor, T. Nomiyama, D. Bruemmer, F. Kojima, L.J. Crofford. Growth factors and cytokines: Emphasis on their role in wound healing and atherosclerosis. Current Anesthesia & Critical Care (2006) 17, 13-20 62. Nomiyama T, Nakamachi T, Gizard F, Heywood EB, Jones KL, Ohkura N, Kawamori R, Conneely OM, Bruemmer D. The NR4A orphan nuclear receptor NOR1 is induced by platelet-derived growth factor and mediates vascular smooth muscle cell proliferation. J Biol Chem. 2006 Nov 3;281(44):33467-76. 63. Mita T, Watada H, Ogihara T, Nomiyama T, Ogawa O, Kinoshita J, Shimizu T, Hirose T, Tanaka Y, Kawamori R. Eicosapentaenoic acid reduces the progression of carotid intima-media thickness in patients with type 2 diabetes. Atherosclerosis, 2007 Mar;191(1):162-7. 64. Ogawa D, Nomiyama T, Nakamachi T, Heywood EB, Stone JF, Berger JP, Law RE, Bruemmer D. Activation of Peroxisome Proliferator-Activated Receptor {gamma} Suppresses Telomerase Activity in Vascular Smooth Muscle Cells. Circ Res. 2006 Apr 14;98(7):e50-9. 65. Nishiyama K, Tanaka Y, Nakajima K, Mokubo A, Atsumi Y, Matsuoka K, Watada H, Hirose T, Nomiyama T, Maeda S, Kawamori R. Polymorphism of the solute carrier family 12 (sodium/chloride transporters) member 3, SLC12A3, gene at exon 23 (+78G/A: Arg913Gln) is associated with elevation of urinary albumin excretion in Japanese patients with type 2 diabetes: a 10-year longitudinal study. Diabetologia. 2005 Jul;48(7):1335-8. 66. Watada H, Nomiyama T, Kawamori R. Mechanism of progression of atherosclerosis in patients with impaired glucose tolerance (IGT). Nihon Rinsho. 2005 Feb;63 Suppl 2:101-6. (in Japanese) 67. Takayanagi N, Onuma T, Kato S, Nishiyama K, Nomiyama T, Kawamori R. Association between LDL particle size and postprandial increase of remnant-like particles in Japanese type 2 diabetic patients. Diabetes Res Clin Pract. 2004 Dec;66(3):245-52. 68. Nomiyama T, Igarashi Y, Taka H, Mineki R, Uchida T, Ogihara T, Choi JB, Uchino H, Tanaka Y, Maegawa H, Kashiwagi A, Murayama K, Kawamori R, Watada H, Reduction of Insulin Stimulated Glucose Uptake by Peroxynitrite is Concurrent with Tyrosine-nitration of Insulin Receptor Substrate-1. Biochem Biophys Res Commun 2004 Jul 30;320(3):320:639-47. 69. Shimo-Nakanishi Y, Hasebe T, Suzuki A, Mochizuki H, Nomiyama T, Tanaka Y, Nagaoka I, Mizuno Y, Urabe T, Functional effects of NAD(P)H oxidase p22phox C242T mutation in human leukocytes and association with thrombotic cerebral infarction. Atherosclerosis 2004;175:109-115 70. Nomiyama T, Tanaka Y, Piao L, Hattori N, Uchino H, Watada H, Kawamori R, Ohta S, Accumulation of Somatic Mutation in mitochondrial DNA and Atherosclerosis in Diabetic Patients. Ann NY Acad Sci. 2004 Apr;1011:193-204 71. Ogihara T, Watada H, Kanno R, Ikeda F, Nomiyama T, Nakao A, German MS, Kojima I, Kawamori R, p38 mitogen-activated protein kinase is involved in activin A- and HGF-mediated expression of pro-endocrine gene neurogenin 3 in AR42J-B13 cells. J Biol Chem. 2003 June 13;278(24);21693-700 72. Takagi M, Tanaka Y, Yamasaki Y, Yamamoto M, Hori M, Nakaniwa T, Niwa M, Uchino H, Tamura Y, Nomiyama T, Watada H, Kawamori R, Responsiveness of insulin-induced cardiac sympathetic nerve activation associates with blood pressure regulation in diabetics. Am J Physiol Endocrinol Metab. 2003 May;284(5):E1022-6 73. Nakajima K, Tanaka Y, Nomiyama T, Ogihara T, Ikeda F, Kanno R, Iwashita N, Sakai K, Watada H, Onuma T, Kawamori R, RANTES Promoter Genotype Is Associated With Diabetic Nephropathy in Type 2 Diabetic Subjects. Diabetes Care. 2003 Mar;26(3):892-8 74. Nomiyama T, Tanaka Y, Piao L, Nagasaka K, Sakai K, Ogihara T, Nakajima K, Watada H, Kawamori R, The polymorphism of manganese superoxide dismutase is associated with diabetic nephropathy in Japanese type 2 diabetic patients. J Hum Genet.2003 Mar;48(3):138-41 75. Piao L, Tanaka Y, Nomiyama T, Nakajima K, Ogihara T, Miwa S, Urabe T, Watada H, Kawamori R, Combined Genotypes of ACE and NADPH Oxidase p22phox Associated with Somatic Mutation of mtDNA and Carotid Intima-Media Thickness in Japanese Patients with Type 2 Diabetes Mellitus. Curr Ther Res. 2002 Dec;63(12):842-852 76. Nomiyama T, Tanaka Y, Hattori N, Nishimaki K, Nagasaka K, Kawamori R, Ohta S, Accumulation of somatic mutation in mitochondrial DNA extracted from peripheral blood cells in diabetic patients. Diabetologia. 2002 Nov;45(11):1577-83. 77. Nakajima K, Tanaka Y, Nomiyama T, Ogihara T, Piao L, Sakai K, Onuma T, Kawamori R, Chemokine receptor genotype is associated with diabetic nephropathy in Japanese with type 2 diabetes. Diabetes. 2002 Jan;51(1):238-42. 78. Matsunaga H, Tanaka Y, Tanaka M, Gong JS, Zhang J, Nomiyama T, Ogawa O, Ogihara T, Yamada Y, Yagi K, Kawamori R, Antiatherogenic mitochondrial genotype in patients with type 2 diabetes. Diabetes Care. 2001 Mar;24(3):500-3

研究テーマ

糖尿病の合併症と併存症

研究業績（論文）

1. Teragawa H, Morimoto T, Fujii Y, Ueda T, Sakuma M, Shimabukuro M, Arasaki O, Node K, Nomiyama T, Ueda S. Effect of anagliptin versus sitagliptin on renal function : subanalyzes from the REASON trial. Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy. 2022 March 3 ;15 :685-94.
2. Tanaka Y, Iwaya C, Kawanami T, Hamaguchi Y, Horikawa T, Shigeoka T, Yanase T, Kawanami D, Nomiyama T. Combined treatment with glucagon-like peptide-1 receptor agonist exendin-4 and metformin attenuates breast cancer growth. Diabetol Int. 2021 Nov 25;13(3):480-492
3. Yamamoto L, Yamashita S, Nomiyama T, Kawanami T, Hamagichi Y, Shigeoka T, Horikawa T, Tanaka Y, Yanase T, Kawanami D, Iwasaki A. Sodium-glucose cotransporter 2 inhibitor canagliflozin attenuates lung cancer cell proliferation in vitro. Diabetol Int 2021 Feb 16 ;12(4) :389-398
4. Teragawa H, Morimoto T, Fujii Y, Ueda T, Sakuma M, Shimabukuro M, Arasaki O, Node K, Nomiyama T, Ueda S. Effect of anagliptin versus sitagliptin on inflammatory markers : sub-analysis from REASON trial. Diabetes Metab Syndr Obes 2020 Dec 15 :13 ;4993-5001
5. Furuhashi M, Sakuma I, Morimoto T, Higashiura Y, Sakai A, Matsumoto M, Sakuma M, Shimabukuro M, Nomiyama T, Arasaki O, Node K, Ueda S. Differential effect of DPP-4 inhibitors, anagliptin and sitagliptin, on PCSK9 levels in patients with type 2 siabetes mellitus who are receiving statin therapy. J Atheroscler Thromb 2020 Dec 18. Doi : 10.5551
6. Horikawa T, Kawanami T, Hamaguchi Y, Tanaka Y, Kita S, Ryorin R, Takashi Y, Tanabe M, Yanase T, Kawanami D, Nomiyama T. Pemafibrate, a PPAR alpha agonist, attenuates neointima formation after vascular injury in mice fed normal chow and a high-fat diet. Heliyon 2020 Nov 6 ;6(11) :e05431.
7. Nomiyama T. Can SGLT2 inhiitor be used for diabetes mellitus or vascular diseases ? J Atheroscler Thromb 2020 Nov 1 ;27(11) :1139-1140.
8. Furuhashi M, Sakuma I, Morimoto T, Higashiura Y, Sakai A, Matsumoto M, Sakuma M, Shimabukuro M, Nomiyama T, Arasaki O, Node K, Ueda S. Independent and distinct association of FABP4 and FABP5 with metabolic parameters in type 2 diabetes mellitus. Front Endocrinol (Lausanne). 2020 Sep 23 ;11 :575557.
9. Furuhashi M, Sakuma I, Morimoto T, Higashiura Y, Sakai A, Matsumoto M, Sakuma M, Shimabukuro M, Nomiyama T, Arasaki O, Node K, Ueda S. Treatment with anagliptin, a DPP-4 inhibitor, decrease FABP4 concentration in patients with type 2 diabetes mellitus at a high risk for cardiovascular disease who a receiving statin therapy. Cardiovasc Diabetol 2020 June ;9(1) :154.
10. Shigeoka T, Nomiyama T, Kawanami T, Hamaguchi Y, Horikawa T, Tanaka T, Irie S, Motonaga R, Hamanoue N, Tanabe M, Nabeshima K, Tanaka M, Yanase T, Kawanami D. Activation of overexpressed GLP-1R attenuates prostate cancer growth by inhibiting cell cycle progression. J Diabetes Investig 2020 Mar 7; 11(3):1137-1149.
11. Terawaki Y, Iwaya C, Nomiyama T, Shimono D, Horikawa T, Fujimura-Tanaka Y, Shigeoka T, Hamanoue N, Motonaga R, Tanabe M, Yanase T, Kawanami D. Efficacy and safety of a combination of an insulin secretagogue and a dipeptidyl peptidase-4 inhibitor in Japanese patients with type 2 diabetes mellitus ; the repaglinide glucose oscillation study in Fukuoka (REGO-F). Daibetol Int 2020 Feb ;11(3) :274-282.
12. Hirai H, Higa M, Morimoto T, Sakuma M, Arasaki O, Nomiyama T, Ueda S, Shimabukuro M. Dissimilar effects of anagliptin and sitagliptin on lipoprotein subclass in standard or strong statin-treated patients with type-2 diabetes mellitus : a subanalysis of the REASON (Randomized Evaluation of Anagliptin versus Sitagliptin on Low-Density LipoproteiN Cholesterol in Diabetes) trial. J Clin Med 2019 Dec 30 ;9(1) :93.
13. Komatsu S, Nomiyama T, Numata T, Kawanami T, Hamaguchi Y, Iwaya C, Horikawa T, Tanaka YF, Hamanoue N, Motonaga R, Tanabe M, Inoue R, Yanase T, Kawanami D. SGLT2 inhibitor ipragliflozin attenuates breast cancer cell proliferation. Endocr J 2020 Jan 28;67(1):99-106.
14. Chihara A, Tanaka A, Morimoto T, Sakuma M, Shimabukuro M, Nomiyama T, Arasaki O, Ueda S, Node K. Differences in lipid metabolism between anagliptin and sitagliptin in patients with type 2 diabetes on statin therapy : a secondry analysis of the REASON trial. Cardiovasc Diabetol 2019 Nov 16;18(1):158
15. Morimoto T, Sakuma M, Tokushige A, Natsuaki M, Asahi T, Shimabukuro M, Nomiyama T, Arasaki O, Node K, Ueda S. Randomized evaluation of anagliptin vs sitagliptin on low-density lipoprotein cholesterol in diabetes (REASON) trial : a 52 week, open-label, radomized clinical trial. Sci Rep 2019 Jun 12 ;9(1) :8537
16. Fujihara Y, Hamanoue N, Yano H, Tanabe M, Akehi Y, Nomiyama T, Yanase T. High sex hormone-binding globulin concentration is a risk factor for high fibrosis-4 index in middle-aged Japanese men. Endocr J 2019 Jul 28;66(7):637-645.
17. Takahashi H, Nomiyama T, Terawaki Y, Horikawa T, Kawanami T, Hamaguchi Y, Tanaka T, Motonaga R, Fukuda T, Tanabe M, Yanase T. Combined treatment with DPP-4 inhibitor linagliptin and SGLT2 inhibitor empagliflozin attenuates neointima formation after vascular injury in diabetic mice. Biochem Biophys Rep 2019 Apr 19 ;18 :100640.
18. Ohe K, Tanaka T, Horita Y, Harada Y, Yamasaki T, Abe I, Tanabe M, Nomiyama T, Kobayashi K, Enjoji M, Yanase T. Circular IRE-type RNAs of the NR5A1 gene are formed in adrenocortical cells. Biochem Biophys Res Commun 2019 Apr 23;512(1):1-6
19. Muta Y, Tanaka T, Hamaguchi Y, Hamanoue N, Motonaga R, Tanabe M, Nomiyama T, Nawata H, Yanase T. Selective androgen receptor modulator, S42 has anabolic effects on cultured myotubes. Biochem Biophys Rep 2019 Jan 15 ;17 :177-181
20. Takahashi H, Nomiyama T, Terawaki Y, Kawanami T, Hamaguchi Y, Tanaka T, Tanabe M, Bruemmer D, Yanase T. Glucagon-like peptide-1 receptor agonist exendin-4 attenuates neuron- derived orphan receptor 1 expression in vascular smooth muscle cells. J Atheroscler Thromb 2019 Feb 1 ;26(2) : 183-197
21. Nomiyama T, Shimono D, Horikawa T, Fujimura Y, Ohsako T, Terawaki Y, Fukuda T, Motonaga R, Tanabe M, Yanase T. Efficacy and safety of sodium–glucose cotransporter 2 inhibitor ipragliflozin on glycemic control and cardiovascular parameters in Japanese patients with type 2 diabetes mellitus; Fukuoka Study of Ipragliflozin (FUSION). Endocr J 2018 Aug 27;65(8):859-867
22. Kawanami T, Tanaka T, Hamaguchi Y, Nomiyama T, Nawata H, Yanase T. Selective androgen receptor modulator S42 suppresses prostate cancer cell proliferation. Endocrinology 2018 Apr 1;159(4):1774-1792.
23. Ueda S, Shimabukuro M, Arasaki O, Node K, Nomiyama T, Morimoto T. Effect of anagliptin and sitagliptin on low-density lipoprotein cholesterol in type 2 diabetic patients with dyslipidemia and cardiovascular risk : rationale and study design of the REASON trial. Cardiovasc Drug Ther 2018 Feb ;32(1) :73-80.
24. Iwaya C, Nomiyama T, Komatsu S, Kawanami T, Hamaguchi Y, Yoshinaga Y, Yamashita S, Tanaka T, Terawaki Y, Tanabe M, Nabeshima K, Iwasaki A, Yanase T. Exendin-4, a glucagon-like peptide-1 receptor agonist, attenuates breast cancer growth by inhibiting NF-kB activation. Endocrinology 2017 Dec 1 ;158(12) :4218-4232.
25. Yanase T, Kawanami T, Tanaka T, Tanabe M, Nomiyama T. Impact of metabolic disorders on prostate cancer growth : Androgen and insulin resistance. Reprod Med Biol 2017 ;16 :252-257
26. Hamanoue N, Tanabe M, Tanaka T, Akehi Y, Murakami J, Nomiyama T, Yanase T. A high score on the aging males’ symptoms scale is associated with insulin resistance in middle-aged men. Endocr J 2017 May 30 ;64(5) :521-530
27. Akehi Y, Hashimoto Y, Meren J, Tanabe M, Nomiyam T, Yanase T. Postpartum hypothalamic adorenal insufficiency with remission : A rare case. Endoc J 2017 Feb 27 ;64(2) :157-162
28. Fukuda T, Tanaka T, Hamaguchi Y, Kawanami T, Nomiyama T, Yanase T. Augmented growth hormone secretion and Stat3 phosphorylation in an aryl hydrocarbon receptor interacting protein (AIP)-disrupted somatotroph cell line. PLOS ONE 2016 ;11(10) :e0164131
29. Nomiyama T, Yanase T. GLP-1 receptor agonist as treatment for cancer as well as diabetes : beyond glucose control. Expert Review of Endocrinology & Metabolism 2016 ; 11(4), 357-364
30. Tanabe M, Motonaga R, Terawaki Y, Nomiyama T, Yanase T. Prescription of oral hypoglycemic agents in patients with type-2 diabetes mellitus : a retrospective cohort study using Japanese hospital database. J Diabete Invest 2017 Mar ;8(2) :227-234
31. Tsutsumi Y, Nomiyama T, Kawanami T, Hamagichi Y, Terawaki Y, Tanaka T, Murase K, Motonaga R, Tanabe M, Yanase T. Combined treatment with Exendin-4 and metformin attenuates prostate cancer growth. PLOS ONE 2015 Oct 6 ;10(10) :e0139709
32. Tanabe M, Nomiyama T, Motonaga R, Murase K, Yanase T. Reduced vascular events in type 2 diabetes by biguanide relative to sulfonylurea : study in a Jananese Hopital Database. BMC Endocr Disord 2015 Sep 17 ; 15(1) :49
33. Aoyagi N, Umemoto G, Nomiyama T, Yoshimura C, Ota C, Miyazaki S, Murase K, Nagaishi R, Watanabe K, Yanase T, Kikuta T. Rapid improvement of blood glucose level after prosthetic mandibular advancement in apatient with diabetes mellitus and obstructive sleep apnea. Diabetes Res Open J 2015 ; 1(3) : 67-71
34. Aoyagi N, Umemoto G, Nomiyama T, Yoshimura C, Ota C, Miyazaki S, Murase K, Nagaishi R, Yanase T, Kikuta T. Short-term effect of prosthetic mandibular advancement on glycemic control in diabetic patients with obstructive sleep apnea syndrome. Med Bull Fukuoka Univ 2015 ; 41(1), 145-152
35. Terawaki Y, Nomiyama T, Takahashi H, Tsutsumi Y, Murase K, Nagaishi R, Tanabe M, Kudo T, Kobayashi K, Yasuno T, Nakashima H, Yanase T. Efficacy of dipeptidyl peptidase-4 inhibitor linagliptin in patients with type 2 diabetes undergoing hemodialysis. Diabetol Metab Syndr 2015 May 17;7:44.
36. Zhao Y, Nomiyama T, Findeisen HM, Qing H, Aono J, Heywood EB, Bruemmer D. Epigenetic regulation of the NR4A orphan nuclear receptor NOR1 by histone acetylation. FEBS Lett 2014 Dec 20 ;588(24) :4825-30.
37. Terawaki Y, Nomiyama T, Kawanami T, Hamaguchi Y, Takahashi H, Tanaka T, Murase K, Nagaishi R, Tanabe M, Yanase T. Dipeptidyl peptidase-4 inhibitor linagliptin attenuates neointima formation after vascular injury. Cardiovasc Diabetol 2014, 13 :154
38. Tanabe M, Akehi Y, Nomiyama T, Murakami J, Yanase T. Total testosterone is the most valuable indicator of metabolic syndrome among various testosterone values in middle-aged Japanese men. Endocrin J 2015;62(2):123-32.
39. Nomiyama T, Kawanami T, Irie S, Hamaguchi Y, Terawaki Y, Murase K, Tsutsumi Y, Nagaishi R, Tanabe M, Morinaga H, Tanaka T, Mizoguchi M, Nabeshima K, Tanaka M, Yanase T. Exendin-4, a glucagon-like peptide-1 receptor agonist, attenuates prostate cancer growth. Diabetes 2014 Nov;63(11):3891-905.
40. Murase K, Nagaishi R, Takenoshita H, Nomiyama T, Akehi Y, Yanase T, Prevalence and clinical characteristics of primary aldosteronism in Japanese patients with type 2 diabetes mellitus and hypertension. Endocr J 2013 Aug 31;60(8):967-76.
41. Akehi Y, Kawate H, Murase K, Nagaishi R, Nomiyama T, Nomura M, Takayanagi R, Yanase T, Proposed diagnostic criteria for subclinical Cushing’s syndrome associated with adorenal incidentaloma. Endocr J 2013 Jul 30 ;60(7) :903-12
42. Terawaki Y, Nomiyama T, Akehi Y, Takenoshita H, Nagaishi R, Tsutsumi Y, Murase K, Nagasako H, Hamanoue N, Sugimoto K, Takada A, Ito K, Abe Y, Sasatomi Y, Ogahara S, Nakashima H, Saito T, Yanase T, The efficacy of incretin therapy in patients with type 2 diabetes undergoing hemodialysis. Diabetology and Metab Synd 2013 Feb 28;5(1):10
43. Ervinna N, Mita T, Yasunari E, Azuma K, Tanaka R, Fujimura S, Sukmawati D, Nomiyama T, Kanazawa A, Kawamori R, Fujitani Y, Watada H. Anagliptin, a DPP-4 inhibitor, suppresses proliferation of vascular smooth muscles and monocyte inflammatory reaction and attenuates atherosclerosis in male apo E-deficient mice. Endocrinology 2013 Mar ;154(3) :1260-70
44. Noda K, Zhang B, Iwata A, Nishikawa H, Ogawa M, Nomiyama T, Miura S, Sakou H, Matsuo K, Yahiro E, Yanase T, Saku K Lifestyle changes through the use of delivered meals and dietary counseling in a single-blind study: the STYLIST study. Circ J 2012 June;76(6)1335-1344
45. Mita T, Azuma K, Goto H, Jin WL, Arakawa M, NomiyamaT, Suzuki R, Kubota N, Tobe K, Kadowaki T, Fujitani Y, Hirose T, Kawamori R, Watada H. IRS-2 deficiency in macrophages promotes their accumulation in the vascular wall. Biochem Biophys Res Commun 2011 Dec 2;415(4):545-50
46. Nomiyama T, Akehi Y, Takenoshita H, Nagaishi R, Terawaki Y, Nagasako H, Kudo T, Kodera T, Kobayashi K, Urata H, Yanase T, members of CHAT. Contributing factors related to efficacy of the dipeptidyl peptidase-4 inhibitor sitagliptin in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract. 2012 Feb ;95(2) :e27-8
47. Gizard F, Zhao Y, Findeisen HM, Qing H, Cohn D, Heywood EB, Jones KL, Nomiyama T, Bruemmer D. Transcriptional regulation of the S-Phase kinase-associated protein 2 by the NR4A orphan nuclear receptor NOR1 in vascular smooth muscle cells. J Biol Chem 2011 Oct 14 ;286(41) :38485-93
48. Goto H, Nomiyama T, Mita T, Yasunari E, Azuma K, Komiya K, Arakawa M, Jin WL, Kanazawa A, Kawamori R, Fujitani Y, Hirose T, Watada T. Exendin-4, a glucagon-like peptide-1 receptor agonist, reduces intimal thickening after vascular injury. Biochem Biophys Res Commun 2011 Feb 4;405(1):71-84
49. Zhao Y, Howatt DA, Gizard F, Nomiyama T, Findeisen HM, Heywood EB, Jones KL, Conneely OM, Daugherty A, Bruemmer. Deficiency of the NR4A orphan nuclear receptor NOR1 decreases monocyte adhesion and atherosclerosis. Circ Res. 2010 Aug 20;107(4):501-11.
50. Mita T, Goto H, Azuma K, Jin WL, Nomiyama T, Fujitani, Hirose T, Kawamori R, Watada H. Impact of insulin resistance on enhanced monocyte adhesion to endothelial cells and atherosclerosis independeny of LDL cholesterol level. Biochem Biophys Res Commun 2010 May 14;395(4):477-83.
51. Arakawa M, Mita T, Azuma K, Ebato C, Goto H, Nomiyama T, Fujitani Y, Hirose T, Kawamori R, Watada H. Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes 2010 Apr;59(4):1030-7.
52. Nomiyama T, Watada H, ARB as a drug for diabetic microangiopathy. Nihon. Rinsho 2009 Apr;67(4):777-82. (in Japanese)
53. Tamura Y, Watada H, Tanaka Y, Daimaru N, Nomiyama T, Sakuraba K, Sawaki K, Kawamori R. Preliminary report: mitochondrial DNA 5178 polymorphism in male elite Japanese endurance runners. Matabolism 2009 Jan;59(1):62-3.
54. Nomiyama T, Zhao Y, Gizard F, Findeisen HM, Heywood EB, Jones KL, Conneely OM, Bruemmer D. Deficiency of the NR4A Neuron-Derived Orphan Receptor-1 Attenuates Neointima Formation After Vascular Injury. Circulation 2009 Feb 3;119(4):577-86.
55. Gizard F, Nomiyama T, Zhao Y, Findeisen HM, Heywood EB, Jones KL, Stales B, Bruemmer D. The PPAR (alpha)/p16INK4a Pathway Inhibits Vascular Smooth Muscle Cell Proliferation by Repressing Cell Cycle-Dependent Telomerase Activation. Circ Res. 2008 Nov 7;103(10):1155-63.
56. Nomiyama T, Bruemmer D. Liver X receptor as therapeutic targets in metabolism and atherosclerosis. Curr Atheroscler Rep. 2008 Feb;10(1):88-95
57. Tamura Y, Watada H, Igarashi Y, Nomiyama T, Onishi T, Takahashi K, Doi S, Katamoto S, Hirose T, Tanaka Y, Kawamori R. Short-term effects of dietary fat on intramyocellular lipid in sprinters and endurance runners. Metabolism 2008 Mar; 57(3):373-9
58. Nomiyama T, Perez-Tilve D, Ogawa D, Gizard F, Zhao Y, Heywood EB, Jones KL, Kawamori R, Cassis LA, Tschop MH, Bruemmer D. Osteopontin mediates obesity-induced adipose tissue macrophage infiltration and insulin resistance in mice. J Clin Invest 2007 Oct 1;117(10):2877-2888
59. Nakamachi T, Nomiyama T, Gizard F, Heywood EB, Jones KL, Zao Y, Fuentes L, Takebayashi K, Aso Y, Staels B, Inukai T, Bruemmer D. PPARalpha agonists suppress osteopontin expression in macrophages and decrease plasma levels in patients with type 2 diabetes. Diabetes 2007 Jun;56(6): 1662-7
60. Tamura Y, Ogihara T, Uchida T, Ikeda F, Kumashiro N, Nomiyama T, Sato F, Hirose T, Tanaka Y, Mochizuki H, Kawamori R, Watada H. Amelioration of glucose tolerance by hepatic inhibition of nuclear factor kappaB in db/db mice. Diabetologia. 2007 Jan;50(1):131-41
61. M. Kapoor, T. Nomiyama, D. Bruemmer, F. Kojima, L.J. Crofford. Growth factors and cytokines: Emphasis on their role in wound healing and atherosclerosis. Current Anesthesia & Critical Care (2006) 17, 13-20
62. Nomiyama T, Nakamachi T, Gizard F, Heywood EB, Jones KL, Ohkura N, Kawamori R, Conneely OM, Bruemmer D. The NR4A orphan nuclear receptor NOR1 is induced by platelet-derived growth factor and mediates vascular smooth muscle cell proliferation. J Biol Chem. 2006 Nov 3;281(44):33467-76.
63. Mita T, Watada H, Ogihara T, Nomiyama T, Ogawa O, Kinoshita J, Shimizu T, Hirose T, Tanaka Y, Kawamori R. Eicosapentaenoic acid reduces the progression of carotid intima-media thickness in patients with type 2 diabetes. Atherosclerosis, 2007 Mar;191(1):162-7.
64. Ogawa D, Nomiyama T, Nakamachi T, Heywood EB, Stone JF, Berger JP, Law RE, Bruemmer D. Activation of Peroxisome Proliferator-Activated Receptor {gamma} Suppresses Telomerase Activity in Vascular Smooth Muscle Cells. Circ Res. 2006 Apr 14;98(7):e50-9.
65. Nishiyama K, Tanaka Y, Nakajima K, Mokubo A, Atsumi Y, Matsuoka K, Watada H, Hirose T, Nomiyama T, Maeda S, Kawamori R. Polymorphism of the solute carrier family 12 (sodium/chloride transporters) member 3, SLC12A3, gene at exon 23 (+78G/A: Arg913Gln) is associated with elevation of urinary albumin excretion in Japanese patients with type 2 diabetes: a 10-year longitudinal study. Diabetologia. 2005 Jul;48(7):1335-8.
66. Watada H, Nomiyama T, Kawamori R. Mechanism of progression of atherosclerosis in patients with impaired glucose tolerance (IGT). Nihon Rinsho. 2005 Feb;63 Suppl 2:101-6. (in Japanese)
67. Takayanagi N, Onuma T, Kato S, Nishiyama K, Nomiyama T, Kawamori R. Association between LDL particle size and postprandial increase of remnant-like particles in Japanese type 2 diabetic patients. Diabetes Res Clin Pract. 2004 Dec;66(3):245-52.
68. Nomiyama T, Igarashi Y, Taka H, Mineki R, Uchida T, Ogihara T, Choi JB, Uchino H, Tanaka Y, Maegawa H, Kashiwagi A, Murayama K, Kawamori R, Watada H, Reduction of Insulin Stimulated Glucose Uptake by Peroxynitrite is Concurrent with Tyrosine-nitration of Insulin Receptor Substrate-1. Biochem Biophys Res Commun 2004 Jul 30;320(3):320:639-47.
69. Shimo-Nakanishi Y, Hasebe T, Suzuki A, Mochizuki H, Nomiyama T, Tanaka Y, Nagaoka I, Mizuno Y, Urabe T, Functional effects of NAD(P)H oxidase p22phox C242T mutation in human leukocytes and association with thrombotic cerebral infarction. Atherosclerosis 2004;175:109-115
70. Nomiyama T, Tanaka Y, Piao L, Hattori N, Uchino H, Watada H, Kawamori R, Ohta S, Accumulation of Somatic Mutation in mitochondrial DNA and Atherosclerosis in Diabetic Patients. Ann NY Acad Sci. 2004 Apr;1011:193-204
71. Ogihara T, Watada H, Kanno R, Ikeda F, Nomiyama T, Nakao A, German MS, Kojima I, Kawamori R, p38 mitogen-activated protein kinase is involved in activin A- and HGF-mediated expression of pro-endocrine gene neurogenin 3 in AR42J-B13 cells. J Biol Chem. 2003 June 13;278(24);21693-700
72. Takagi M, Tanaka Y, Yamasaki Y, Yamamoto M, Hori M, Nakaniwa T, Niwa M, Uchino H, Tamura Y, Nomiyama T, Watada H, Kawamori R, Responsiveness of insulin-induced cardiac sympathetic nerve activation associates with blood pressure regulation in diabetics. Am J Physiol Endocrinol Metab. 2003 May;284(5):E1022-6
73. Nakajima K, Tanaka Y, Nomiyama T, Ogihara T, Ikeda F, Kanno R, Iwashita N, Sakai K, Watada H, Onuma T, Kawamori R, RANTES Promoter Genotype Is Associated With Diabetic Nephropathy in Type 2 Diabetic Subjects. Diabetes Care. 2003 Mar;26(3):892-8
74. Nomiyama T, Tanaka Y, Piao L, Nagasaka K, Sakai K, Ogihara T, Nakajima K, Watada H, Kawamori R, The polymorphism of manganese superoxide dismutase is associated with diabetic nephropathy in Japanese type 2 diabetic patients. J Hum Genet.2003 Mar;48(3):138-41
75. Piao L, Tanaka Y, Nomiyama T, Nakajima K, Ogihara T, Miwa S, Urabe T, Watada H, Kawamori R, Combined Genotypes of ACE and NADPH Oxidase p22phox Associated with Somatic Mutation of mtDNA and Carotid Intima-Media Thickness in Japanese Patients with Type 2 Diabetes Mellitus. Curr Ther Res. 2002 Dec;63(12):842-852
76. Nomiyama T, Tanaka Y, Hattori N, Nishimaki K, Nagasaka K, Kawamori R, Ohta S, Accumulation of somatic mutation in mitochondrial DNA extracted from peripheral blood cells in diabetic patients. Diabetologia. 2002 Nov;45(11):1577-83.
77. Nakajima K, Tanaka Y, Nomiyama T, Ogihara T, Piao L, Sakai K, Onuma T, Kawamori R, Chemokine receptor genotype is associated with diabetic nephropathy in Japanese with type 2 diabetes. Diabetes. 2002 Jan;51(1):238-42.
78. Matsunaga H, Tanaka Y, Tanaka M, Gong JS, Zhang J, Nomiyama T, Ogawa O, Ogihara T, Yamada Y, Yagi K, Kawamori R, Antiatherogenic mitochondrial genotype in patients with type 2 diabetes. Diabetes Care. 2001 Mar;24(3):500-3

研究者

教育活動

【学校法人順天堂】研究者情報データベース

研究業績詳細

野見山 崇（ノミヤマ タカシ）

野見山崇（ノミヤマタカシ）